Aimmune Therapeutics Inc. (NASDAQ:AIMT) gapped up before the market opened on Thursday . The stock had previously closed at $11.13, but opened at $11.16. Aimmune Therapeutics shares last traded at $11.59, with a volume of 66,126 shares trading hands.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, May 20th. Bank of America Corp. restated a “buy” rating on shares of Aimmune Therapeutics in a report on Monday, May 16th. Piper Jaffray Cos. restated an “overweight” rating and set a $38.00 price target on shares of Aimmune Therapeutics in a report on Tuesday, May 17th. Finally, Wedbush restated an “outperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a report on Monday, May 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Aimmune Therapeutics presently has an average rating of “Buy” and a consensus target price of $33.40.

The firm’s 50-day moving average is $11.96 and its 200-day moving average is $14.14. The company’s market cap is $495.13 million.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.03. Equities research analysts expect that Aimmune Therapeutics Inc. will post ($1.70) earnings per share for the current year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the firm’s stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total value of $3,655,200.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

An institutional investor recently raised its position in Aimmune Therapeutics stock. Aisling Capital LLC raised its stake in shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 6.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,990,000 shares of the company’s stock after buying an additional 170,000 shares during the period. Aimmune Therapeutics accounts for 9.5% of Aisling Capital LLC’s portfolio, making the stock its 4th largest position. Aisling Capital LLC owned 7.08% of Aimmune Therapeutics worth $55,166,000 as of its most recent SEC filing.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.